Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Biotecnología

Ms. Maggie  Niewidok

Company Sec.

Mr. Daniel  Astudillo B.A., B.Com., M.B.A.

Head of Marketing

Dr. John K. A. Prendergast Ph.D.

Executive Chairman

Ms. Michele Keryn Diliza BA (Journ), BSc (Med Sci)

Chief Scientific Director & Executive Director

Mr. James Hamilton-Bray Graham GAICD

Chief Executive Officer, MD & Executive Director

Ms. Michele Keryn Dilizia BA (Journ), BSc (Med Sci)

Dr. Justin  Ward

Principal Quality Chemist & Executive Director

Mr. Arthur  Kollaras

Principal Engineer & Head of Manufacturing

Mr. Justin  Reynolds

Chief Financial Officer

Thomas  Jarrett

Operations Mang.

Nombre	Capitalización
hVIVO plc	0M
VistaGen Therapeutics, Inc.	0M
BioVaxys Technology Corp.	0M
MedMira Inc.	0M
Regenicin, Inc.	0M
Vascular Biogenics Ltd.	0M
CorMedix Inc.	0M
Wave Life Sciences Ltd.	0M
Immuron Limited	0M
Aptevo Therapeutics Inc.	0M

Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd Lista de competidores

Principales competidores